Hypolipemic activity of plafibride.
This paper reports on the hypolipemic activity of N-2-(p-chlorophenoxy)-isobutyryl-N' morpholinomethylurea (plafibride, ITA 104) in experimental animals. In Triton hypercholesterolemic animals, the activity of plafibride was greater than that of clofibrate, and was more evident in the total lipids and reducing the serum lactacidemia than the cholesterol serum levels. Plafibride protected the rats and the mice almost completely against the increase in serum lactacidemia due to the administration of olive oil. In normolipemic rats the activity of plafibride was greater than that of clofibrate on triglycerides but not on cholesterol. Plafibride increased the serum alpha-lipoprotein fraction, too.
D000818:Animals; D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000031:analogs & derivatives*; D002995:Clofibric Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D004285:Dogs; D005230:Fatty Acids, Nonesterified / Q000097:blood; D000960:Hypolipidemic Agents; D008074:Lipoproteins / Q000097:blood; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D011092:Polyethylene Glycols / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D014280:Triglycerides / Q000097:blood
D005230:Fatty Acids, Nonesterified; D000960:Hypolipidemic Agents; D008074:Lipoproteins; D014280:Triglycerides; D011092:Polyethylene Glycols; D002995:Clofibric Acid; C016894:plafibride; D002784:Cholesterol; D002994:Clofibrate; C016811:tyloxapol